Why Every Adult Over 50 Should Know About ApoB and hsCRP

The Number One Killer Is Not Going Away

Heart disease has been the leading cause of death in the United States for more than a century, and it still is. In 2023 alone, cardiovascular disease killed over 915,000 Americans, which works out to roughly one in every four deaths. For adults over 50, the numbers are even more sobering. By the time you reach your sixties, there is approximately a 70-75%chance you already have some form of cardiovascular disease, whether you feel it or not.

Most of us have had our cholesterol checked at some point. If our LDL (the so-called “bad cholesterol”) comes back in the normal range, we breathe a sigh of relief and move on. But here is a fact that should stop you in your tracks: nearly 75%of people hospitalized for a heart attack had LDL cholesterol levels that would have been considered normal or even optimal by standard guidelines. That means the test most doctors rely on to decide whether you are at risk is missing the majority of people who go on to have heart attacks.

This article is about two simple, inexpensive blood tests that do a far better job of predicting who is headed for trouble. They are called apolipoprotein B (ApoB) and high-sensitivity C-reactive protein (hsCRP). Each one captures a different piece of the puzzle. Together, they paint a picture of cardiovascular risk that standard cholesterol testing simply cannot provide.

New Studies Show That Combining These Two Markers Is the Key

Three major studies published in 2024 and 2025 have brought this issue into sharp focus. Their message is consistent and powerful: when you measure both a lipid biomarker (reflecting the particles that build up in your arteries) and an inflammatory biomarker (reflecting the fire that makes plaques dangerous), you get a far more accurate prediction of who will have a heart attack or stroke than either marker provides on its own.

The largest of these studies, led by Dr. Paul Ridker and published in the New England Journal of Medicine in 2024, followed nearly 28,000 initially healthy women for 30 years. The researchers measured three biomarkers at the start of the study: hsCRP (for inflammation), LDL cholesterol (for lipid burden), and lipoprotein(a). Over three decades, 3,662 of these women experienced their first major cardiovascular event. Each biomarker predicted risk independently, but hsCRP was the strongest single predictor. The truly striking finding was what happened when all three biomarkers were elevated simultaneously. Women in the highest category for all three markers had a risk of coronary heart disease that was 3.7 times higher than women in the lowest category. No single biomarker came close to that level of prediction.

A second study, published in the European Heart Journal in 2025 by Markus and colleagues, confirmed these findings in a much larger and more diverse population. Using data from over 322,000 participants in the UK Biobank (both men and women, followed for nearly 14 years), the researchers found that when LDL cholesterol, lipoprotein(a), and hsCRP were all above the 75th percentile, participants faced a 77% higher risk of a major cardiovascular event compared to those with all three below the 75th percentile. Among people already taking cholesterol-lowering medication, hsCRP emerged as the strongest predictor of remaining risk, outperforming even LDL cholesterol.

A third study, also published in the European Heart Journal in 2025 by Kraaijenhof and colleagues, independently validated these findings in over 17,000 initially healthy Europeans followed for more than 20 years. The combined top-quintile status across all three biomarkers yielded a risk 2.6 times higher in women. The authors concluded that the time has come for universal screening of all three biomarkers in both primary and secondary prevention.

These studies used LDL cholesterol as their lipid biomarker. But as we will see in the next section, extensive evidence shows that ApoB is a more accurate measure of the same thing. This means that combining ApoB with hsCRP would likely perform even better than the pairings tested in these landmark trials.

What Is ApoB, and Why Is It Better Than Standard Cholesterol Testing?

To understand why ApoB matters, it helps to know a little about how cholesterol travels through your bloodstream. Cholesterol does not float freely in your blood. Instead, it rides inside tiny protein-wrapped packages called lipoproteins. The most familiar of these is LDL, but there are others, including VLDL, IDL, lipoprotein(a), and chylomicron remnants. Every one of these particles can penetrate the walls of your arteries and contribute to plaque formation.

Here is the critical point: every single one of these dangerous particles contains exactly one molecule of a protein called apolipoprotein B. When your doctor measures ApoB, the result is essentially a direct count of every atherogenic particle in your bloodstream. Standard LDL cholesterol, by contrast, measures the total mass of cholesterol riding inside LDL particles. It tells you how much cholesterol is there, but not how many particles are carrying it.

This distinction matters enormously, especially for adults over 50. Conditions that become increasingly common with age, such as metabolic syndrome, type 2 diabetes, insulin resistance, and abdominal obesity, cause the liver to produce large numbers of small, cholesterol-depleted LDL particles. If you have this pattern, your LDL cholesterol can look reassuringly normal while your actual particle count is dangerously high. Research from the MESA study found that roughly half of individuals show a meaningful mismatch between their LDL particle number and LDL cholesterol levels. When the two disagree, cardiovascular risk tracks with particle count rather than cholesterol content.

A comprehensive 2025 review published in the Journal of Clinical Lipidology examined 15 studies involving more than 593,000 participants and found that ApoB outperformed LDL cholesterol as a cardiovascular risk predictor in every study that directly compared them. Mendelian randomization studies, which use genetic variants as natural experiments to test cause and effect, have shown that ApoB, not LDL cholesterol, is the true causal lipid driver of coronary heart disease. And a large meta-analysis of more than 233,000 subjects estimated that switching from LDL cholesterol-based screening to ApoB-based screening could prevent roughly 800,000 additional heart attacks over a decade in the United States.

The clinical community is taking notice. The 2026 ACC/AHA Dyslipidemia Guideline now explicitly recommends ApoB measurement, stating that it directly quantifies the number of atherogenic lipoproteins and provides a more accurate measure of atherogenic particle burden than LDL cholesterol.

What Is hsCRP, and What Does Inflammation Have to Do With Heart Disease?

Atherosclerosis is not simply a plumbing problem in which cholesterol gradually clogs your arteries the way grease clogs a drain. It is fundamentally an inflammatory disease. When atherogenic particles are trapped within arterial walls, the body mounts an immune response. White blood cells swarm to the area, engulf the trapped lipoproteins, and form foam cells. Over time, these foam cells accumulate into fatty streaks and eventually into full-blown plaques. But the real danger comes when inflammation destabilizes a plaque, causing it to crack open and trigger a blood clot. That clot is what causes a heart attack or stroke.

High-sensitivity CRP is a marker of this inflammatory process. It does not tell you where the inflammation is occurring, but it tells you how much of it is happening throughout your body. And the evidence connecting hsCRP to cardiovascular events is remarkably strong.

Dr. Paul Ridker first showed in 1997 that men with the highest CRP levels had three times the risk of heart attack compared to men with the lowest levels. In 2000, he demonstrated that hsCRP was the strongest single predictor of cardiovascular events among 12 biomarkers tested in women, outperforming every lipid measure.

Two landmark clinical trials then moved hsCRP from a prediction tool to a proven basis for treatment decisions. The JUPITER trial in 2008 enrolled nearly 18,000 apparently healthy people who had normal LDL cholesterol but elevated hsCRP. Half received a statin and half received a placebo. The statin cut LDL cholesterol by 50% and hsCRP by 37%, and major cardiovascular events dropped by 44%. The benefit was so dramatic that the trial was stopped early. The CANTOS trial in 2017 went even further by testing an anti-inflammatory drug (canakinumab) that reduced inflammation without lowering cholesterol. Even so, cardiovascular events fell by 15%. This trial was proof of concept: reducing inflammation alone, independent of any change in cholesterol, prevents heart attacks.

Most recently, a 2023 collaborative analysis in The Lancet examined over 31,000 patients already taking statins and found that, among people whose cholesterol was well controlled, residual inflammatory risk (measured by hsCRP) was a far stronger predictor of future events than residual cholesterol risk. Patients in the highest hsCRP quartile had nearly 2.7 times the risk of dying from cardiovascular causes compared to those in the lowest quartile. LDL cholesterol, by contrast, was essentially neutral as a predictor once patients were on statins.

Why Standard Cholesterol Testing Leaves So Many People Exposed

The disconnect between standard lipid panels and actual cardiovascular events is not a small statistical curiosity. It is a gaping hole in our screening system. The most striking evidence comes from a study of nearly 137,000 patients hospitalized with coronary artery disease, which found that roughly three out of four had LDL cholesterol levels that fell within recommended guidelines at the time of their hospitalization. Half of the levels were classified as “optimal.” These were not people whose doctors had missed a warning sign on a blood test. Their blood tests looked fine.

Even among people already being treated with statins, major trials consistently show substantial residual event rates. Statins reduce cardiovascular events by about 30%, which is meaningful, but 70% of the risk persists. That residual risk is driven by factors that LDL cholesterol alone does not capture.

This is exactly why combining ApoB and hsCRP makes both biological and clinical sense. ApoB addresses the lipid measurement gap by identifying patients whose LDL cholesterol appears normal but whose atherogenic particle count is elevated. This is particularly common in people with metabolic syndrome, type 2 diabetes, and obesity, conditions that become more prevalent with every decade after 50. hsCRP addresses the inflammatory gap by identifying people whose arteries are actively inflamed and whose plaques are vulnerable to rupture, even when their lipid levels are well controlled.

A 2025 UK Biobank analysis of more than 375,000 participants provided a direct mechanistic link between these two pathways. Among individuals with discordantly high ApoB (elevated particle count despite normal LDL cholesterol), CRP mediated a measurable portion of their excess cardiovascular risk. Inflammation is not just an independent risk factor. It is part of the mechanism by which excess atherogenic particles cause disease.

What This Means for You

The practical takeaway from this research is straightforward. If you are over 50 and relying on a standard lipid panel to assess your cardiovascular risk, you are seeing only part of the picture. ApoB and hsCRP are both widely available blood tests that can be ordered by any physician. They are inexpensive and require no special preparation beyond a routine blood draw.

Together, these two tests capture the two fundamental biological pathways that drive atherosclerotic cardiovascular disease. ApoB tells you how many dangerous particles are circulating and available to penetrate your artery walls. hsCRP tells you how actively your immune system is fueling the inflammatory process that makes plaques unstable and prone to rupture.

Neither test alone tells the complete story. The Ridker 2024 study showed that hazard ratios climbed from about 1.3 with one elevated biomarker to 2.6 or higher with all biomarkers elevated. That is a multiplicative interaction that no single test can capture.

If you have not had these tests, consider asking your doctor about them at your next visit. If your results show elevated ApoB, elevated hsCRP, or both, you and your doctor have actionable information that can guide decisions about lifestyle changes, medications, and monitoring. The goal of cardiovascular prevention is not to wait for a heart attack and then react. It is to identify risk early, while there is still time to change the trajectory.

References

Why Every Adult Over 50 Should Know About ApoB and hsCRP

Dr. Daniel Thomas, DO, MS